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Abstract 
Background: Large-scale mapping of Plasmodium falciparum infection prevalence relies on opportunistic assemblies 
of infection prevalence data arising from thousands of P. falciparum parasite rate (PfPR) surveys conducted worldwide. 
Variance in these data is driven by both signal, the true underlying pattern of infection prevalence, and a range of fac-
tors contributing to ‘noise’, including sampling error, differing age ranges of subjects and differing parasite detection 
methods. Whilst the former two noise components have been addressed in previous studies, the effect of different 
diagnostic methods used to determine PfPR in different studies has not. In particular, the majority of PfPR data are 
based on positivity rates determined by either microscopy or rapid diagnostic test (RDT), yet these approaches are 
not equivalent; therefore a method is needed for standardizing RDT and microscopy-based prevalence estimates prior 
to use in mapping.
Methods: Twenty-five recent Demographic and Health surveys (DHS) datasets from sub-Saharan Africa provide child 
diagnostic test results derived using both RDT and microscopy for each individual. These prevalence estimates were 
aggregated across level one administrative zones and a Bayesian probit regression model fit to the microscopy- ver-
sus RDT-derived prevalence relationship. An errors-in-variables approach was employed to account for sampling error 
in both the dependent and independent variables. In addition to the diagnostic outcome, RDT type, fever status and 
recent anti-malarial treatment were extracted from the datasets in order to analyse their effect on observed malaria 
prevalence.
Results: A strong non-linear relationship between the microscopy and RDT-derived prevalence was found. The 
results of regressions stratified by the additional diagnostic variables (RDT type, fever status and recent anti-malarial 
treatment) indicate that there is a distinct and consistent difference in the relationship when the data are stratified by 
febrile status and RDT brand.
Conclusions: The relationships defined in this research can be applied to RDT-derived PfPR data to effectively con-
vert them to an estimate of the parasite prevalence expected using microscopy (or vice versa), thereby standardizing 
the dataset and improving the signal-to-noise ratio. Additionally, the results provide insight on the importance of RDT 
brands, febrile status and recent anti-malarial treatment for explaining inconsistencies between observed prevalence 
derived from different diagnostics.
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Background
Large-scale maps of Plasmodium falciparum infection 
prevalence [1–3] are increasingly used to inform dis-
ease control planning, implementation and evaluation at 
national to global scales [4], and as a basis for disease bur-
den estimation and the monitoring of progress towards 
international targets [4–7]. Mapping at the continental 
or global scale relies on opportunistic assemblies of data 
on infection prevalence arising from thousands of P. fal-
ciparum parasite rate (PfPR) surveys conducted in dif-
ferent countries. The between-site variance observed in 
these PfPR estimates arises from both an underlying sig-
nal component: the variation of the true infection preva-
lence and the residual noise component, attributable, not 
only to the inherent random error, but also to a range 
of confounding factors that reduce the comparability of 
PfPR measurements from different surveys, most notably, 
immunological differences in the age ranges of subjects 
surveyed [8] and differences in parasite detection meth-
ods. Whilst random error and age-standardization have 
been addressed in previous mapping efforts, the effect of 
different diagnostic methods has not. Previous research 
has defined the functional relationship between micros-
copy and polymerase chain reaction (PCR) detection [9], 
but little research has explored the functional differences 
between microscopy and rapid diagnostic test (RDT). 
Given that the majority of PfPR data are based on positiv-
ity rates measured by either microscopy or RDT, and that 
the sensitivity and specificity of these approaches are not 
identical [10], it is crucial to understand the functional 
differences between these two approaches.
Detection of parasite infection via microscopy has 
formed the mainstay of modern PfPR surveys for many 
decades [11]. Giemsa-stained thick smear microscopy 
under ideal conditions where stains are prepared cor-
rectly and the slide is analysed by an expert is highly 
accurate for infection diagnosis at densities above 100 
parasites per µL [12]. Since the early 2000s, however, 
economically preferable RDTs have become widely 
used in field locations as they allow quick diagnosis 
through antigen-detection without the need for labora-
tory equipment. Figure  1 illustrates the increasing role 
of RDT measurements in the global assembly of PfPR 
surveys maintained by the Malaria Atlas Project (MAP). 
This increase is mirrored in clinical settings, where the 
introduction of RDTs has enabled improvements in the 
proportion of suspected malaria cases receiving parasi-
tological diagnosis (e.g., rising from 20 to 62 % between 
2006 and 2013 in the African public sector and with over 
half of reported cases in 2013 identified by RDTs [4]).
World Health Organization (WHO) guidelines state 
that all RDTs used for malaria diagnosis pass the follow-
ing criteria in the WHO Malaria RDT product testing 
programme: have a panel detection score of at least 75 % 
at 200 parasites per µL, with a false positive rate <10 and 
<5 % of tests deemed invalid [13]. RDTs used in PfPR sur-
veys undergo extensive testing as part of WHO quality 
assurance procedures [14]. However, despite these proce-
dures, the relative performance of RDTs versus micros-
copy in the field is influenced by a wide range of factors 
that cannot be fully captured in standardized quality 
assurance tests. RDTs have been shown to become inef-
fective through poor storage [15], and can display false 
positivity due to the perseverance of antigens detected in 
the blood after both anti-malarial treatment and parasite 
clearance [16, 17]. Despite these limitations, no simple 
Fig. 1 Breakdown of African PfPR data points in the MAP database by diagnostic type [polymerase chain reaction (PCR), rapid diagnostic test (RDT) 
and microscopy] as of November 2014. a Overall proportion, and b a time series by survey year from 1995 to 2014. The reduced numbers in 2013 
and 2014 are to be expected due to the lag time between data collection and its subsequent release
Page 3 of 10Mappin et al. Malar J  (2015) 14:460 
adjustment factors currently exist to functionally map 
between RDT-derived PfPR measurements and those 
likely to be observed using microscopy.
To address the need for cross-comparability of micros-
copy- and RDT-derived PfPR measurements, a large 
database of individual-level parasitological outcomes 
tested, using both methods, was assembled from national 
household surveys conducted in sub-Saharan Africa. A 
hierarchical Bayesian model was then developed to cap-
ture the functional divergence in PfPR measured using 
the two techniques. The extent of this divergence was 
further explored in sub-analyses stratified using the pres-
ence or absence of symptomatic infection (i.e., fever), 
recent treatment with effective anti-malarial drugs and 
the type and brand of RDT used.
Methods
Data collection
The Demographic and Health Surveys (DHS) Programme 
collects nationally representative health and socio-eco-
nomic information from over 90 countries worldwide 
through cross-sectional household surveys [18]. Typically, 
malaria testing within DHS Programme is limited to chil-
dren under five years old. For this study, children from 
sub-Saharan African DHS datasets, whose malaria diag-
nostic outcome was recorded using both microscopy and 
RDT, were selected. Table 1 lists the 25 DHS Programme 
that met these inclusion criteria as of 15 July, 2015, which 
were tabulated from 118,078 individuals tested for falcipa-
rum malaria. The administrative zone (ADMIN1) of resi-
dence and the RDT and microscopy diagnostic outcome 
was recorded for each individual. Where available, the fol-
lowing additional factors were extracted: (1) RDT brand; 
(2) RDT type used whether the RDT detected histidine-
rich protein 2 (HRP2) or HRP2 and pan-Plasmodium lac-
tate dehydrogenase (pLDH) or HRP2 and Plasmodium 
vivax-specific pLDH; (3) whether the individual had been 
febrile within the last two weeks; and (4) whether febrile 
individuals had received treatment with artemisinin-
based combination therapy (ACT) anti-malarial within 
the previous 2 weeks.
Modelling the relationship between microscopy‑ 
and RDT‑derived PfPR
Individual-level data on infection status were aggre-
gated within ADMIN1 zones across sub-Saharan Africa, 
and microscopy-derived (PfPRMIC) and RDT-derived 
(PfPRRDT) infection prevalence were calculated for each 
zone. Any estimates from <10 individuals were excluded. 
A Bayesian probit regression was fit to the resulting 458 
pairwise PfPR observations with an errors-in-variables 
approach [19]. This approach was employed to account 
for sampling error in both the RDT-derived measurement 
and the microscopy-derived measurement. In hierarchi-
cal Bayesian notation,
where niMIC and niRDT are the number of microscopy and 
RDT positive counts, respectively, with nitot the total 
number of individuals tested in each of the i = 1 … nobs 
site-specific aggregations; likewise, piMIC and piRDT are 
the long-run PfPRMIC and PfPRRDT; φ−1(·) denotes the 
inverse probit function that maps the linear predictor 
within the range of valid probabilities (zero to one); α and 
β are the unknown parameters of the regression model; 
μi and σi are the mean and standard deviation of the Nor-
mal mixture component from which the i-th φ−1(piRDT) is 
drawn; each μi and σi pair is drawn from a single realisa-
tion, F, of the Dirichlet process, DP(GΘ,  m), with refer-
ence density, GΘ, (here a single Normal controlled by the 
hyper-parameters, Θ) and concentration index m; while 
π represents a family of priors and hyperpriors chosen 
for conjugacy with the upper layers.
The use of Bayesian inference with an errors-in-variables 
structure requires the specification of a prior for the baseline 
distribution of long-run RDT-derived prevalence, which in 
the above is handled by the highly flexible semi-parametric 
form known as the Dirichlet process mixture model [20]. To 
facilitate posterior simulation via Gibbs sampling for ordi-
nary probit regressions, Albert and Chib [21] propose an 
augmented variable method based on the introduction of an 
additional unit-variance, Normal latent variable per binary 
response, i.e., a non-observed or inferred variable. Here 
this approach is extended to the errors-in-variables context 
with a further latent variable for each binary observation in 
the RDT-derived measurement and couple the procedure 
to a Polya urn sampler for the Dirichlet process (from the 
DPpackage library in R [22]). Leave-one-out cross-valida-
tion was employed to evaluate the statistical performance 
of the fitted model to predict the microscopy-derived preva-

























(5){µi, σi}(i = 1, . . . , nobs) ∼ F
(6)F ∼ DP(GΘ ,m)
(7)α,β ,Θ ,m ∼ pi ,
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Analysis of factors influencing the relationship 
between PfPRMIC and PfPRRDT
To explore possible factors driving residual noise in the 
relationship between microscopy and RDT-derived prev-
alence, the Bayesian regression analysis described above 
was repeated on various stratified sub-sets of the data: 
by fever status, treatment status, RDT type, and RDT 
brand (see Fig.  2 for more details). For each factor pre- 
and post-stratification akaike information criterion (AIC) 
scores [23] were compared to determine whether the 
stratification substantially improved the net information 
content of the fitted regression model.
Results
Modelled PfPRMIC versus PfPRRDT relationship
Figure  3a shows the aggregated prevalence data points 
and their associated uncertainties, the (point-wise) 
median and 95  % credible interval curves from the 
posterior of the probit regression model, as well as the 
line of equality for reference. A systematic tendency for 
PfPRRDT to exceed PfPRMIC when measured in the same 
population was observed, indicating that RDTs tend to 
give more false positives than false negatives, i.e., most 
(71.6  %) points in Fig.  3a lie below line of equality. The 
best-fit regression function relating PfPRRDT to PfPRMIC 
was:
 
The results from the leave-one-out cross-validation 
procedure applied to this model are shown in Fig.  3b. 
The correlation coefficient between the observed and 
predicted PfPRMIC was 0.921, the mean square error was 
0.84 %, and the mean absolute error was 5.77 % indicating 









Table 1 Surveys included in  analysis, the number of  individuals included within  each survey, the RDT type, the RDT 
brand, the RDT model if known, and the age range of patients screened for parasitaemia within each survey
MIS Malaria Indicator Survey, DHS Demographic Health Survey, EA&P anaemia and malaria parasitaemia survey




RDT type RDT brand RDT model Age range 
of individuals
Angola 2011 MIS 3322 21 HRP2/Pv-pLDH SD Bioline 05FK80 6–59 months
Benin 2011–2012 Standard DHS 3736 12 HRP2 Paracheck 30301100 1–59 months
Burkina Faso 2010 Standard DHS 5741 13 HRP2 Paracheck 30301100 6–59 months
Burundi 2012 MIS 3718 18 HRP2/pan-pLDH SD Bioline 05FK60 6–59 months




2013–2014 Standard DHS 8135 26 HRP2 SD Bioline 05FK50 6–59 months
The Gambia 2013 Standard DHS 3262 8 HRP2/pan-pLDH SD Bioline Unknown 6–59 months
Guinea 2012 Standard DHS 3198 8 HRP2/pan-pLDH First Response I16FRC30 6–59 months
Liberia 2009 MIS 4960 18 HRP2 Paracheck Unknown 6 months–6 years
Liberia 2011 MIS 3060 18 HRP2 First Response I13FRC30 6–59 months
Madagascar 2011 MIS 6821 23 HRP2/pan-pLDH CareStart Unknown 6–64 months
Madagascar 2013 MIS 6147 22 HRP2/pan-pLDH CareStart Unknown 6–65 months
Malawi 2012 MIS 2105 3 HRP2 SD Bioline 05FK50 6–59 months
Mali 2010 Special EA&P 1716 9 HRP2 Paracheck Unknown 6–59 months
Mali 2012–2013 Standard DHS 5640 6 HRP2 Paracheck 30301100 0–83 months
Mozambique 2011 Standard DHS 4891 13 HRP2/Pv-pLDH SD Bioline 05FK80 6–59 months
Nigeria 2010 MIS 5127 38 HRP2 Paracheck 30301100 6–59 months
Rwanda 2010 Standard DHS 4887 5 HRP2 First Response I13FRC30 6–73 months
Senegal 2008–2009 MIS 3947 15 HRP2 Paracheck 30301100 6–59 months
Senegal 2010–2011 Standard DHS 4603 14 HRP2 Paracheck 30301100 6–77 months
Senegal 2012–2013 Continuous DHS 7252 14 HRP2/pan-pLDH SD Bioline 05FK60 6–76 months
Senegal 2014 Continuous DHS 6760 14 HRP2/pan-pLDH SD Bioline Unknown 6–59 months
Tanzania 2011–2012 Standard AIS 7264 30 HRP2/pan-pLDH SD Bioline 05FK60 6–59 months
Togo 2013–2014 Standard DHS 3861 6 HRP2/pan-pLDH First Response Unknown 6–59 months
Uganda 2009 MIS 3998 95 HRP2 Paracheck 30301100 0 month–5 years
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Analysis of factors influencing the relationship 
between PfPRMIC and PfPRRDT
Figure 4a shows the data stratified by individual fever sta-
tus and the resulting fitted curves. The prevalence rate 
estimated by RDT amongst non-febrile children is more 
closely aligned with the prevalence estimated by micros-
copy than that amongst febrile children. The difference in 
AIC scores between the original (non-stratified) model 
and that stratified by fever status confirms that the strati-
fied model performs substantially better (see Table 2).
Recent treatment with ACT has a marked effect on the 
observed relationship between microscopy and RDT-
derived prevalence as seen in Fig.  4b, greatly increasing 
PfPRRDT relative to PfPRMIC. The ‘taken an ACT’ sub-
set relationship is less precisely determined (note the 
larger spread and larger confidence intervals in Fig. 4b). 
In addition to the smaller sample size, this likely reflects 
the irregular occurrence of false positivity due to per-
severance of antigens after anti-malarial treatment and 
parasite clearance [16, 17]. Although the stratified model 
is preferred for its lower AIC score (see Table  2), the 
unpredictability of the false positivity among the taken-
ACT children indicates that RDT diagnosis is not ideal 
and that microscopy would provide a more conclusive 
diagnosis.
In contrast, there is far less divergence between the 
prevalence rates estimated by RDTs detecting HRP2 
alone compared with HRP2 and pan-pLDH, or HRP2 and 
P. vivax-pLDH, as seen in Fig. 4c, and indeed the strati-
fied model in this case is not favoured by the AIC score. 
Therefore, there is no benefit in stratifying by RDT type.
Figure  4d shows the relationship of the PfPRMIC 
and PfPRRDT by RDT brand. The CareStart (HRP2/
pan-pLDH) has a near one–one relationship (param-
eter values being estimated near to α equal 0 and β 
equal 1) whereas First Response (HRP2) and SD Bioline 
(HRP2) diverge to PfPRRDT, being almost double PfPR-
MIC at PfPRRDT at 40 %. The AIC score of the RDT brand 
PfPR RDT to Microscopy 
relaonship dataset
118,039 individuals across 458 
administration zones
95,617 individuals febrile symptoms 
in the last two weeks is known
Febrile
25,164 individuals across 400 
administration zones
Non-Febrile 
70,453 individuals across 431 
administration zones
21,436 individuals with fever 
symptoms and ACT usage 
known
Taken an ACT 
2,919 individuals across 92 
administration zones
Not taken an ACT
18,517 individuals across 359 
administration zones
HRP2 type
61,565 individuals across 284 
administration zones
HRP2/pan-pLDH type
48,276 individuals across 142 
administration zones
HRP2/Pv-pLDH type
8,198 individuals across 32 
administration zones
118,039 individuals RDT type 
used is known
CareStart HRP2/pan-pLDH
12,968 individuals across 45 administration zones
First Response HRP2/pan-pLDH
7,059 individuals across 14 administration zones
First Response HRP2
7,938 individuals across 22 administration zones
Paracheck HRP2
39,460 individuals across 219 administration 
zones
SD Bioline HRP2/pan-pLDH
28,249 individuals across 83 administration zones
SD Bioline HRP2/Pv-pLDH
8,198 individuals across 32 administration zones
SD Bioline HRP2
14,167 individuals across 43 administration zones
118,039 individuals RDT 






Fig. 2 The stratified sub-sets of the data based on fever status, ACT usage, RDT type, and RDT brand
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stratified model is significantly lower than the non-strati-
fied model, favouring stratification.
The combination of febrile status and RDT brand was 
additionally explored. The AIC score of the febrile status 
with RDT brand stratified model was lower than the non-
stratified model, indicating the stratified model to be pre-
ferred (see Table 2). The combination of ACT usage and 
RDT brands was not possible to explore with our dataset 
due to low sample sizes for the children taken an ACT by 
RDT brand.
In summary, the AIC scores are lower for the models 
stratified by febrile status, ACT usage among febrile indi-
viduals, RDT brands and febrile status with RDT brands 
than the non-stratified model, and are thus considered 
the preferred models. When applying the conversion 
formula to an RDT-derived prevalence, cross-sectional 
population, survey dataset, if the population has a known 
febrile status, known ACT usage among febrile individu-
als, or RDT brand used is known, the preferred method 
for estimating the equivalent microscopy prevalence 
would, therefore, be applying the model specific to that 
population. The resulting regression function parameters 
with 95 % credible intervals for each of the data sub-sets 
are listed in Table 3.
Discussion
The models developed in this paper provide a means of 
converting RDT-derived PfPR measurements into esti-
mates compatible with microscopy-derived PfPR or vice 
versa. As such, the approach provides an indispensable 
tool for data standardization, designed to decrease the 
overall uncertainty associated with models that utilize 
PfPR data derived using differing diagnostic techniques. 
This research also illustrates the utility of ancillary fac-
tors when converting PfPR metrics to reduce the residual 
noise. Those wishing to apply the conversions developed 
here can do so using the coefficients in Table 3.
The models were derived using a hierarchical Bayesian 
framework implementing an errors-in-variables probit 
regression with a highly flexible, semi-parametric prior 
(the Dirichlet process mixture model) for marginaliz-
ing over uncertainty in the distribution of RDT-derived 
prevalence. The statistical reliability and predictive per-
formance of this model has been demonstrated through 
leave-one-out cross-validation.
The field setting of the joint microscopy and RDT prev-
alence measurements in the DHS dataset distinguishes 
the present analysis from previous formal verification 
studies for RDT accuracy [14]; thus the results presented 
offer a complementary picture of RDT performance 
outside of control conditions, but require care in their 
interpretation. For instance, while one may be confident 
in supposing that the observed strength of recent treat-
ment with ACT as a factor for overdiagnosis by RDT sur-
veillance is likely due to the known lag between asexual 
parasite clearance and the antigenic-response targeted 
by RDTs [24], the apparent role of febrile status in RDT 
overdiagnosis is less easily explained. Previous studies 
have also observed higher RDT false positives among 
febrile patients [25, 26]. Uncovering the causal relation-
ship will be important for the accuracy of analyses fore-
casting likely cost-benefit analyses of different designs for 
Fig. 3 a Pairwise PfPRMIC and PfPRRDT observations (blue dots) with sampling error bounds (blue crosses) with the (point-wise) median curve and 
95 % credible intervals from the Bayesian probit regression (solid black line and dashed black lines) overlaid. b The correlation between observed and 
predicted microscopy prevalence inferred from leave-one-out cross-validation. The line of equality (grey line) is included for reference in both panels
Page 7 of 10Mappin et al. Malar J  (2015) 14:460 
Fig. 4 The fitted regression functions with the 95 % credible intervals overlaid on the paired microscopy and RDT derived prevalence data points 
with their individual error-bounds, for the following stratifications. a febrile (dark blue) and non-febrile children (green), b febrile children who have 
taken an ACT in the last 2 weeks (purple) and febrile children who have not taken an ACT in the last 2 weeks (red), c RDT detected HRP2 (red), RDT 
detected HRP2 and pan-pLDH (dark blue) and RDT detected HRP2 and P. vivax-pLDH (yellow), d RDT brand CareStart detected HRP2 and pLDH 
(yellow), RDT brand First Response detected HRP2 and pan-pLDH (dark blue), RDT brand First Response detected HRP2 (green), RDT brand Paracheck 
detected HRP2 (red), RDT brand SD Bioline detected HRP2 and pan-pLDH (purple), RDT brand SD Bioline detected HRP2 and P. vivax-pLDH (dark grey) 
and RDT brand SD Bioline detected HRP2 (dark green). The line of equality is included in each plot for reference
Table 2 The estimated AIC for each of the models
Model AIC of stratified model AIC model not stratified Preferred model
Febrile/non-febrile (stratified model 1) 8523.86 8756.76 Stratified model
Taken ACT/not taken ACT (stratified model 2) 3700.14 3787.54 Stratified model
RDT type (stratified model 3) 6480.68 6299.77 Not stratified
RDT brands (stratified model 4) 5970.06 6299.77 Stratified model
Febrile/non-febrile with RDT brands 8023.65 8756.76 Stratified model
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the diagnosis and treatment strategies of proposed mass 
screen and treat campaigns [27]. In the absence of further 
data, some insight into the epidemiological processes 
behind the role of febrile status in RDT positivity rates 
may be gained from in silico experiments with mecha-
nistic transmission codes if RDT measurement can be 
modelled immunologically, rather than by proxy through 
asexual density. Similar caveats apply to the interpreta-
tion of the results for the role of RDT brand in shaping 
the observed relationship.
The model incorporates random sampling noise for 
both the RDT and microscopy-derived measurements 
and the systematic noise of the RDT-derived measure-
ments is addressed by exploring the factors that may 
influence the relationship. However, the systematic noise 
of the microscopy-derived measurements have not been 
explored here. There may be factors that are cause sys-
tematic noise to the relationship such as the condition of 
the microscope, microscopist’s training and judgement 
[11]. The data used here are from a consistent resource 
that uses a strict microscopy protocol in national facili-
ties [18] and, therefore, these factors are likely to be mini-
mal. Caution should however be applied when applying 
the presented regression function to microscopy-derived 
prevalence data from inconsistent sources with large var-
iation in their diagnosing protocol.
There has been reports in some regions, mainly in 
South America, of Pf with absent expression of HRP2 
affecting RDT performance [28]. The occurrence of these 
reports have been marginal in sub-Sahara Africa [29, 30] 
and, therefore, unlikely to affect the analysis presented 
here, however caution should be applied when extended 
this to other geographic regions.
Previous evaluations of RDT diagnoses in field settings 
at specific sites (covering a limited range of transmission 
conditions) have identified a strong dependence of RDT 
specificity on age, such that overdiagnosis is most com-
mon amongst young children and much less common 
Table 3 The estimated parameters for the fitted regression function (Eq. 3) and their 95 % credible intervals
Dataset α β
Overall −0.22 (−0.24, −0.21) 0.97 (0.95, 0.99)
Febrile −0.37 (−0.39,−0.34) 0.93 (0.89, 0.97)
Non-febrile −0.15 (−0.17, −0.13) 0.99 (0.96, 1.01)
Taken an ACT −0.65 (−0.72, −0.59) 0.71 (0.59, 0.83)
Not taken an ACT −0.31 (−0.34, −0.27) 0.96 (0.91, 1.00)
HPR2 −0.25 (−0.27, −0.24) 0.95 (0.92, 0.97)
HPR2/pan-pLDH −0.08 (−0.13, −0.04) 1.07 (1.03, 1.11)
HPR2/Pv-pLDH −0.16 (−0.22, −0.10) 0.96 (0.88, 1.03)
CareStart (HPR2/pan-pLDH) −0.01 (−0.15, 0.13) 1.12 (1.01, 1.23)
First Response (HPR2/pan-pLDH) −0.03 (−0.08, 0.01) 0.92 (0.83, 1.02)
First Response (HPR2) −0.52 (−0.58, −0.46) 0.86 (0.81, 0.93)
Paracheck (HPR2) −0.15 (−0.16, −0.13) 0.91 (0.88, 0.94)
SD Bioline (HPR2/pan-pLDH) −0.31 (−0.38, −0.24) 0.94 (0.88, 0.99)
SD Bioline (HPR2/Pv-pLDH) −0.16 (−0.22, −0.10) 0.95 (0.87, 1.03)
SD Bioline (HPR2) −0.53 (−0.56, −0.49) 0.72 (0.65, 0.79)
Febrile with CareStart (HPR2/pan-pLDH) −0.31 (−0.54, 0.02) 1.01 (0.77, 1.34)
Febrile with First Response (HPR2/pan-pLDH) −0.16 (−0.25, −0.07) 0.90 (0.71, 1.12)
Febrile with First Response (HPR2) −0.58 (−0.66, −0.50) 0.84 (0.70, 0.98)
Febrile with Paracheck (HPR2) −0.31 (−0.35, −0.27) 0.86 (0.80, 0.91)
Febrile with SD Bioline (HPR2/pan-pLDH) −0.37 (−0.47, −0.27) 0.96 (0.85, 1.06)
Febrile with SD Bioline (HPR2/Pv-pLDH) −0.32 (−0.43, −0.20) 0.91 (0.75, 1.09)
Febrile with SD Bioline (HPR2) −0.49 (−0.55, −0.44) 0.81 (0.69, 0.95)
Non-febrile with CareStart (HPR2/pan-pLDH) 0.30 (0.08, 0.51) 1.30 (1.15, 1.45)
Non-febrile with First Response (HPR2/pan-pLDH) 0.02 (−0.04, 0.08) 0.89 (0.79, 1.00)
Non-febrile with First Response (HPR2) −0.42 (−0.53, −0.31) 0.93 (0.85, 1.03)
Non-febrile with Paracheck (HPR2) −0.09 (−0.12, −0.07) 0.93 (0.89, 0.97)
Non-febrile with SD Bioline (HPR2/pan-pLDH) −0.21 (−0.36, −0.07) 0.98 (0.87, 1.07)
Non-febrile with SD Bioline (HPR2/Pv-pLDH) −0.12 (−0.19, −0.05) 0.96 (0.87, 1.07)
Non-febrile with SD Bioline (HPR2) −0.53 (−0.58, −0.49) 0.65 (0.56, 0.73)
Page 9 of 10Mappin et al. Malar J  (2015) 14:460 
amongst adults [31]. The results presented here are based 
on the DHS Programme data for children only; hence, 
the fitted relationships cannot be certified for conversion 
of all age prevalence survey data.
Conclusions
The research conducted in this paper offers a robust, 
data-driven approach for converting RDT-derived meas-
urements of PfPR estimates into the more traditional 
microscopy-based measurements. The predictive accu-
racy of the conversion approach was high (correlation 
coefficient >0.9) for the generic, non-stratified model. 
The conversion technique developed here was a neces-
sary precursor to the latest round of PfPR mapping in 
Africa by MAP [32] as it provides a means of includ-
ing several national-level surveys for which only RDT 
data were collected. This technique is likely to become 
increasingly important in forthcoming years due to 
the increased usage of RDTs in P. falciparum-endemic 
countries.
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